Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 18/20 | 0.54 |
| ▸ | VPS4B | O75351 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634954 | 0.89 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL5633530 | 0.86 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL5635450 | 0.83 | KCNH2 (0.55) | KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5633239 | 0.83 | KCNH2 (0.42) | KCNH2VPS4BVCPSLC6A2SLC6A4 | |
| SCHEMBL5634040 | 0.74 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL5634472 | 0.74 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL5633173 | 0.74 | KCNH2 (0.55) | KCNH2SLC6A4SLC6A3 | |
| SCHEMBL5633517 | 0.72 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL5634679 | 0.70 | KCNH2 (0.53) | KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5633732 | 0.70 | KCNH2 (1.00) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| JP-2006526000-A | — | — | 2006-11-16 | — | — | JP | claimed |
| EP-1633343-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Technologies, Inc. (CA) | 2006-03-15 | — | — | EP | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004105750-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | KCNH2 33/4885VPS4B 2248/4885VCP 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.